Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study | Zendy

Babafemi Taiwo | Zendy; Ellen S. Chan | Zendy; Carl J. Fichtenbaum | Zendy; Heather J. Ribaudo | Zendy; Athe Tsibris | Zendy; Karin L. Klingman | Zendy; Joseph J. Eron | Zendy; Baiba Berzins | Zendy; Kevin Robertson | Zendy; Alan Landay | Zendy; Igho Ofotokun | Zendy; Todd T. Brown | Zendy

Open Access

Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study

Author(s) -

Babafemi Taiwo,

Ellen S. Chan,

Carl J. Fichtenbaum,

Heather J. Ribaudo,

Athe Tsibris,

Karin L. Klingman,

Joseph J. Eron,

Baiba Berzins,

Kevin Robertson,

Alan Landay,

Igho Ofotokun,

Todd T. Brown

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ455

Subject(s) - medicine , maraviroc , emtricitabine , darunavir , clinical endpoint , viral load , bone mineral , ritonavir , population , placebo , randomized controlled trial , gastroenterology , osteoporosis , surgery , human immunodeficiency virus (hiv) , antiretroviral therapy , immunology , alternative medicine , environmental health , pathology

There is a need to prevent or minimize bone loss associated with antiretroviral treatment (ART) initiation. We compared maraviroc (MVC)- to tenofovir disoproxil fumarate (TDF)-containing ART.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research